Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers of Exposure and Effect in SREC Users
NCT04003805Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- May 2022
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in Tobacco Use Disorder (TUD), sponsored by Masonic Cancer Center. Primary endpoints: Exposure Biomarkers: Cotinine at 6 weeks, Exposure Biomarkers: NNAL at 6 weeks and 4 more. Started May 2022; status: completed.
02
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT04003805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003805.